Map of Pancreatica Walks and Runs

Monthly Archives: May 2013

Oral thymidylate synthase inhibitor as an Oral Alternative to Gemcitabine?

Especially researchers in Japan have been studying the outcomes of the orally administered drug known as S-1 in the treatment of pancreatic cancer. S-1 is a fluorouracil drug agent (similar to 5FU – fluorouracil), which like 5-FU, functions as an inhibitor of thymidylate synthase. S-1 is comprised of three components: tegafur (a prodrug of 5-fluorouracil), […]

Share Button

The Whipple Procedure in Elderly Patients with Pancreatic Cancer

One of the interesting aspects of the cutting edge of medicine and science as observed over the years is the pendulum swing as new discoveries are made and conclusions rendered, only later to become modified and placed in better context by further research. A case in point is the increasing trend of research results that […]

Share Button

Gemzar PLUS Xeloda for Cancer of the Pancreas

An earlier blog entry (February 14th) referenced a study by UK researchers that suggested the substitution of the drug-agent capecitabine (Xeloda) in place of gemcitabine for the treatment of locally advanced pancreatic cancer.  Now comes another study by different UK researchers who looked at coupling gemcitabine together with Xeloda for the treatment of advanced pancreatic […]

Share Button